To what extent the combined approach of the administration of exogenous activators, together with the application of TPE and the resulting endogenous stimulation of Nrf2, may contribute to a better clinical response in MS will be the subject of future profound investigations. Here, NFE2L2 is linked to myeloid sarcoma.